Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) have earned a consensus rating of “Buy” from the sixteen brokerages that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $29.23.

A number of analysts have recently weighed in on the company. BidaskClub raised Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Credit Suisse Group set a $11.00 price objective on Alder BioPharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, August 24th. Royal Bank of Canada assumed coverage on Alder BioPharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $17.00 price objective for the company. Canaccord Genuity assumed coverage on Alder BioPharmaceuticals in a research report on Thursday, October 26th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Mizuho reissued a “buy” rating and issued a $32.00 price objective on shares of Alder BioPharmaceuticals in a research report on Wednesday, November 8th.

Alder BioPharmaceuticals (NASDAQ ALDR) traded up $0.05 during trading on Monday, hitting $10.75. The stock had a trading volume of 2,557,296 shares, compared to its average volume of 646,479. Alder BioPharmaceuticals has a 52-week low of $8.60 and a 52-week high of $25.45.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.21) by $0.29. During the same period last year, the firm posted ($0.70) earnings per share. research analysts expect that Alder BioPharmaceuticals will post -5.14 earnings per share for the current fiscal year.

In other Alder BioPharmaceuticals news, insider Mark James Litton sold 16,519 shares of Alder BioPharmaceuticals stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $10.80, for a total transaction of $178,405.20. Following the completion of the sale, the insider now owns 116,451 shares of the company’s stock, valued at approximately $1,257,670.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.60% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Teachers Advisors LLC lifted its holdings in shares of Alder BioPharmaceuticals by 6.3% in the 1st quarter. Teachers Advisors LLC now owns 81,614 shares of the biopharmaceutical company’s stock valued at $1,698,000 after buying an additional 4,805 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of Alder BioPharmaceuticals in the 1st quarter valued at about $564,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of Alder BioPharmaceuticals by 22.3% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 209,273 shares of the biopharmaceutical company’s stock valued at $4,353,000 after buying an additional 38,123 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Alder BioPharmaceuticals by 7.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 42,416 shares of the biopharmaceutical company’s stock valued at $486,000 after buying an additional 2,837 shares during the period. Finally, Candriam Luxembourg S.C.A. lifted its holdings in shares of Alder BioPharmaceuticals by 7.3% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 117,000 shares of the biopharmaceutical company’s stock valued at $1,340,000 after buying an additional 8,000 shares during the period. 96.88% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Alder BioPharmaceuticals, Inc. (ALDR) Receives Average Rating of “Buy” from Analysts” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/16/alder-biopharmaceuticals-inc-aldr-receives-average-rating-of-buy-from-analysts.html.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.